Lilly/BMS halt Phase III trial of anticancer necitumumab over blood clot concerns
This article was originally published in Scrip
Lilly and Bristol-Myers Squibb have stopped enrolment in one of their two global Phase III studies evaluating the anticancer necitumumab owing to a risk of it causing blood clots. A second Phase III trial of the antibody will continue after a safety committee evaluation judged that the observered adverse effects were trial-specific and not drug-specific
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.